Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home
  
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down

Return

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players
Bookmark and Share

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Scope of this research

  • Assessment of the revenues of late-stage biomarker technology and services in North America, Europe, Asia and the rest of the world.
  • Details of the key market drivers and restraints in the biomarker sector.
  • Information about microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services.
  • Patent analysis with respect to competitors and geography.
  • Discussion of major pharmaceutical companies, biotechs, contract research organizations and biomarker specialists.

Research and analysis highlights

The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery. Funding from government sources such as the National Institutes of Health has not increased significantly over the last few years.

More than 50% of clinical trials fail in Phase III for a host of reasons, including greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.

Biomarkers play a crucial role in late-stage clinical trials by acting as surrogate endpoints for patient monitoring and stratification. Surrogate endpoints help measure treatment efficacy, and thus facilitate significant cost reductions in the drug development process.

Key reasons to purchase this research

  • Examine and evaluate the growth potential of emerging technologies.
  • Understand biomarker activity in the clinical trials of leading market players.
  • Gain knowledge about the relative importance of biomarker late-stage clinical trials technologies over the next five years.
  • Determine the collaborations and partnerships of the major market players.

Further Information


Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!